Core Viewpoint - FOXO Technologies Inc. has announced the spin-off of its subsidiary FOXO Labs, Inc., which focuses on epigenetics, aiming to enhance business strategy and shareholder value [1][3]. Group 1: Company Overview - FOXO Technologies operates three subsidiaries, including Rennova Community Health, Inc. and Myrtle Recovery Centers, Inc., which provide healthcare services [4]. - FOXO Labs, Inc. is dedicated to improving human health and lifespan through advanced technology and product solutions [5]. Group 2: Epigenetics Business - FOXO Labs is a pioneer in integrating epigenetic biomarkers into underwriting protocols and consumer engagement tools, holding Patent No. 11,817,214 for a machine learning model that uses DNA epigenetic data [1]. - The epigenetic technology developed by FOXO Labs offers insights into health, lifestyle, and longevity from a single saliva sample, eliminating the need for invasive testing [2]. Group 3: Business Strategy and Future Plans - The CEO of FOXO Labs emphasized that the spin-off will create opportunities for a subscription-based revenue model focused on personal health and longevity [3]. - The spin-off strategy allows FOXO shareholders to directly own FOXO Labs while retaining some ownership, simplifying the business model for both entities [3].